CV Sciences (CVSI) Net Cash Flow Growth (1y) (2012 - 2026)
CV Sciences (CVSI) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -1,020.00% |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -91.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -91.64% |
| Dec 31, 2025 | 90.21% |
| Sep 30, 2025 | -209.76% |
| Jun 30, 2025 | 138.59% |
| Mar 31, 2025 | 154.89% |
| Dec 31, 2024 | -59.82% |
| Sep 30, 2024 | 1,168.09% |
| Jun 30, 2024 | -118.85% |
| Mar 31, 2024 | -734.95% |
| Dec 31, 2023 | 38.26% |
| Sep 30, 2023 | -288.00% |
| Jun 30, 2023 | 173.66% |
| Mar 31, 2023 | -90.32% |
| Dec 31, 2022 | -85.26% |
| Sep 30, 2022 | 101.92% |
| Jun 30, 2022 | 51.02% |
| Mar 31, 2022 | -6.75% |
| Dec 31, 2021 | 81.48% |
| Sep 30, 2021 | 35.37% |
| Jun 30, 2021 | -664.72% |